U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 3

1.
Figure 1

Figure 1. Mean values for strength and corticosteroid dosage over time. From: Disease Course and Therapeutic Approach in Dermatomyositis: A Four-Center Retrospective Study of 100 Patients.

1a. Mean strength over time, as measured by proximal manual muscle testing (MMT) score. 1b. Mean corticosteroid dosage (mg/day) over time. Bars indicate one standard error of the mean.

Nicholas E. Johnson, et al. Neuromuscul Disord. ;25(8):625-631.
2.
Figure 3

Figure 3. Mean creatine kinase (CK) over time. From: Disease Course and Therapeutic Approach in Dermatomyositis: A Four-Center Retrospective Study of 100 Patients.

3a. Mean CK level (U/mL) over time. 3b. Relationship of the mean baseline CK to the mean baseline proximal MMT score at baseline. Bars indicate one standard error of the mean.

Nicholas E. Johnson, et al. Neuromuscul Disord. ;25(8):625-631.
3.
Figure 2

Figure 2. Association between initial corticosteroid dosage and strength. From: Disease Course and Therapeutic Approach in Dermatomyositis: A Four-Center Retrospective Study of 100 Patients.

2a. Mean strength over time, as measured by proximal manual muscle testing (MMT) score, stratified by initial corticosteroid dosage (mg/day). 2b. Mean corticosteroid dosage (mg/day) over time, stratified by initial corticosteroid dosage. 2c. The association between corticosteroid dosage and change in strength (proximal MMT score) over all 6–12 month intervals; the corticosteroid dosage associated with the maximum mean improvement in proximal MMT score was 36 mg/day. Bars indicate one standard error of the mean.

Nicholas E. Johnson, et al. Neuromuscul Disord. ;25(8):625-631.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center